
Teladoc (TDOC) Stock Forecast & Price Target
Teladoc (TDOC) Analyst Ratings
Bulls say
Teladoc Health is viewed positively because Integrated Care remains a steady growth engine, with chronic care momentum, healthy 2027 bookings, and management signaling that Teladoc One and recent M&A should support broader expansion. BetterHelp is also improving as its insurance pivot gains traction, with insurance revenue beating expectations, weekly covered sessions reaching 27k, and a projected exit run-rate of at least $200M in 2027 offsetting still-pressured cash-pay demand. That combination supports higher estimates to roughly $2.4B in 2026 revenue and about $303M in 2027 adjusted EBITDA, even as margin risks from advertising and scaling remain a watch point.
Bears say
Teladoc Health is facing a difficult fundamental setup as greater-than-expected pricing pressure, a challenging regulatory environment, and slower consumer adoption threaten both margins and growth. Although 3Q results beat lowered expectations and BetterHelp insurance revenue reached a $140mm annual run rate versus $110mm in 2Q, cash-pay declines are accelerating as management shifts advertising away from the cash-pay business, with 2027 ad spending expected to fall in the mid-to-high-20% range. At the same time, integrated care bookings were “generally inline,” urgent care telehealth is commoditizing, and if BetterHelp cannot convert DTC users to insurance reimbursement, the company risks losing share and failing to restore topline growth in FY27.
This aggregate rating is based on analysts' research of Teladoc and is not a guaranteed prediction by Public.com or investment advice.
Teladoc (TDOC) Analyst Forecast & Price Prediction
Start investing in Teladoc (TDOC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Teladoc (TDOC) Forecast
Teladoc (TDOC) Analyst Forecast & Price Prediction
Start investing in Teladoc (TDOC)
Order type
Buy in
Order amount
Est. shares
0 shares